BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) --  Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, experienced life sciences leader, to the Akari Board of Directors effective September 17, 2024. "I am very honored to have the opportunity to work with this distinguished board of directors to advance the portfolio opportunities," said Mr. Bazemore. "Focusing on Akari's novel lead asset, nomacopan, as well as Peak's innovative antibody-drug-conjugate (ADC) platform in oncology, has the opportunity to bring significant value both for patients and fo

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inf

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari's Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari's Chief Operating Officer effective today. In connection with Ms. Jacques' departure, Akari's board of directors (the "Board") has appointed Dr. Patel as Interim Chief Executive Officer. Dr. Patel has served as a member of the Board sinc

NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors. "Samir is a long-time investor in Akari and brings to us broad life sciences experience and a track record of multiple successful startup companies. I am pleased to welcome him to our Board of Directors at this important time in our company's development," said Ray Prudo, M.D., Akari Chairman. "I am truly honored to have this opportunity to further demonstrate my c

Akari's priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA)Granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation, adding to existing FDA Orphan Drug, Fast Track and Rare Pediatric Disease designationsThe company established a Boston U.S. headquarters office to support expanding operations and the start of registrational Phase 3 clinical trialsStrengthened capabilities with appointment of Beth-Anne Lang, an experienced executive with a long track record of successful

NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs. Ms. Lang has more than 20 years of experience in regulatory strategy, regulatory affairs, and drug development. She will start at Akari in this role on September 1, 2023. "Beth has a long track record of successful drug approvals in the U.S. and rest of world. Her extensive experience will be instrumental as we approach key development milestones and advance our two registrational Phase 3 clinica

NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of industry veteran Wa'el Hashad to the Akari Board of Directors as an independent director. Mr. Hashad, who will serve on both the Audit Committee and Nominating and Governance Committee, brings more than 35 years of biopharmaceutical experience to Akari's Board of Directors with focus on drug approval and commercialization, mergers and acquisitions, and business development. "I am pleased to welcome Wa'el to our Board of Directors" said Ray Prudo, M.D., Ak

Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials across a broad range of therapeutic areas, including specialty and rare diseasesPrior to joining industry, Dr. Neylan spent 12 years in academic medicine, progressing to Professor of Medicine at Emory University and Medical Director of the Emory Renal Transplant Program; he also assumed numerous leadership positions in public policy and professional education, including the presidency of the American Society of Transplantation NEW YORK and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company deve

NEW YORK and LONDON, June 13, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Melissa Bradford-Klug as Chief Operating Officer, effective July 1, 2022. In this position, she will lead business development, including financing and partnering strategies, acceleration of prioritized nomacopan late-stage and preclinical development programs, as well as other business operations. Ms. Klug has more than 25 years of experience as a leader within companies ranging from large global healthcare organizations to biotech startups. She

BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds from both new and existing investors. "We are pleased to announce this financing for Akari Therapeutics," said Samir R. Patel, MD, Interim President and CEO of Akari Therapeutics. "The overwhelming interest from investors allowed the company to upsize the transaction to $7.6 million and highlights the excitement surrou

Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX, "Akari"))) and Peak Bio Inc. (OTC:PKBO, "Peak"))) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak's ADC (antibody drug conjugate) platform technology and Akari's PAS-nomacopan Geographic Atrophy (GA) program. P

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC:PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded pipeline that contains multiple compelling assets span

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC:PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded pipeline that contains multiple compelling assets span

Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment.Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD).Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung.Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to